

Real-World Longitudinal Outcomes of First-Line Aflibercept 8 mg for Treatment-Naïve Diabetic Macular Edema

Björg Debes^{1,2#}, Sarah Tovsgård Kristensen^{1,2#}, Gertrud Dam-Dalgeir³, Celine Lee^{1,2}, Mads Odgaard Mæng^{1,2}, Line Petersen^{4,5}, Henrik Vorum^{1,2}, Yousif Subhi^{6,7}, Omer Trivizki^{8,9}, Marie Ørskov^{1,2}, Lasse Jørgensen Cehofski^{1,2,10}

1. Department of Ophthalmology, Aalborg University Hospital, Denmark
2. Department of Clinical Medicine, Aalborg University, Denmark
3. Department of Research Data and Biostatistics, Aalborg University Hospital, Denmark
4. Department of Ophthalmology, Aarhus University Hospital, Denmark
5. Department of Clinical Medicine, Aarhus University, Denmark
6. Department of Ophthalmology, University Hospital of Southern Denmark, Sønderborg, Denmark
7. Department of Regional Health Research, University of Southern Denmark, Odense, Denmark
8. Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
9. Bascom Palmer Eye Institute, University of Miami, Miami, Florida, Denmark
10. Texas Research Foundation, Retina Consultants of Texas, Houston, Texas, U.S.A.

#Contributed equally to the study

Correspondence to:

Lasse Jørgensen Cehofski
Department of Ophthalmology,
Aalborg University Hospital
Hobrovej 18,
9000 Aalborg, Denmark.
Phone: +45 53558878
E-mail: l.cehofski@rn.dk

Supplementary Table 1 – Descriptive Availability Data[#]

	Data available at day 300*	No data available at day 300*
Baseline characteristics, number of patients		
Patients	52	25
Age (years)	64.9 ± 12.9	67.4 ± 12.4
Sex		
Female	16 (31%)	12 (48%)
Male	36 (69%)	13 (52%)
HbA1c (mmol/mol)	61.4 (13.9)	62.0 ± 19.0
Both eyes included	13 (25%)	6 (24%)
Type of diabetes		
Type 1	14 (27%)	6 (24%)
Type 2	38 (73%)	19 (76%)
Duration of diabetes (years)		
Overall	19.1 ± 13.5	19.4 ± 12.3
Type 1	14 (27%)	6 (25%)
Type 2	38 (73%)	18 (75%)
Baseline characteristics, number of eyes		
Eyes	67	28
Baseline BCVA (ETDRS letters)	68.0 ± 10.0	70.0 ± 8.0
Baseline CRT (μm)	395.0 ± 117.0	333.0 ± 75.0
Proliferative diabetic retinopathy (n)	11 (16%)	11 (39%)
Non-proliferative diabetic retinopathy (n)	56 (84%)	17 (61%)
Previous focal laser (n)	5 (7.5%)	2 (7.1%)
Previous panretinal photocoagulation (n)	14 (22%)	7 (25%)

Descriptive data are given in means ± SD and numbers (%).

[#] Stratified into number of patients and number of eyes to avoid independent data, if a patient has two eyes included.

** To assess potential attrition bias, baseline characteristics (BCVA, age, sex, and diabetes type) were compared between eyes retained at 300 days and those lost to follow-up.*

Abbreviations: BCVA = best-corrected visual acuity; CRT = central retinal thickness.